Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX + GLS-010 + Lenvatinib in AFP-positive Gastric Cancer
NCT05221775Phase 1Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in gastric cancer (GC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Adverse Events at 24 months. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05221775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221775.